Anti-Human IL17A Recombinant Antibody(Bimekizumab)

Name: Anti-Human IL17A Recombinant Antibody(Bimekizumab)
Brand: KMD Bioscience
SKU: YR1328

YR1328

科研级 Bimekizumab ( 比美吉珠单抗 ), Anti-IL17A Recombinant Antibody, Research Grade Bimekizumab

DATASHEET MSDS

Product Description

Alias	科研级 Bimekizumab ( 比美吉珠单抗 ), Anti-IL17A Recombinant Antibody, Research Grade Bimekizumab
Catalog Number	YR1328
Molecular Name	Bimekizumab
Size	1mg, 5mg
Clonity	Monoclonal
Purity	>95% as determined by SDS-PAGE
Concentration	1mg/ml
Antibody Isotype	IgG1 Kappa
Formulation	PBS, pH7.5
Background	Bimekizumab (INN) is a humanized anti-IL17A and IL-17F monoclonal antibody that is being investigated for ankylosing spondylitis, psoriatic arthritis, and psoriasis. This drug is being developed by Belgian pharmaceutical UCB. As of 2018, bimekizumab is undergoing Phase III trials.
CAS Number	1418205-77-2
Application	ELISA, FCM, IP, FuncS, IF, Neut
Storage Condition	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Remarks	This product is for research use only.
Shipping Condition	Shipped on ice packs.
Target	IL17A[Homo sapiens]

Login